Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03615196 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety of USB005 in Healthy Volunteers
A Phase 1 study, sponsored by US Biotest.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03615196: Completed Phase 1 study, sponsored by US Biotest.
NCT03615196 is a Phase 1 study that has completed, run by US Biotest. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03615196, a Phase 1 study, has completed, sponsored by US Biotest.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and pharmacokinetics of USB005 (aclerastide) Ophthalmic Solution.
Interventions
- DRUG USB005 (aclerastide) Ophthalmic Solution
- DRUG USB005 Ophthalmic Solution Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2019-04-02 |
| Phase | Phase 1 |
What the finished NCT03615196 record still lists
NCT03615196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which USB005 (aclerastide) Ophthalmic Solution is the first listed.
NCT03615196 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03615196 about?
NCT03615196 is a clinical study titled "Study of the Safety of USB005 in Healthy Volunteers". This study will evaluate the safety, tolerability and pharmacokinetics of USB005 (aclerastide) Ophthalmic Solution.
What is the current status of trial NCT03615196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-07-25. Estimated completion is 2019-04-02.
What interventions are being tested in trial NCT03615196?
The interventions under investigation include: USB005 (aclerastide) Ophthalmic Solution (DRUG), USB005 Ophthalmic Solution Placebo (DRUG).
Who is sponsoring clinical trial NCT03615196?
This trial is sponsored by US Biotest, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03615196's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI